FGK Clinical Research establishes operational presence in the Netherlands to bolster European clinical trial landscape
[Munich, 10/03/2026] — FGK Clinical Research GmbH, a leading full-service Contract Research Organization (CRO) headquartered in Germany, is thrilled to announce the further expansion of its operative team in the Netherlands. This strategic regional expansion strengthens FGK’s European presence and commitment to high-quality clinical research services. The local Dutch team will support clinical studies in the Netherlands for FGK’s international clients, leveraging the country’s strong reputation as a leading hub for clinical research.
The Netherlands has rapidly emerged as a dynamic hub for biotechnological innovation, attracting significant investment and fostering a vibrant ecosystem for groundbreaking research. Recognizing this fertile environment, FGK Clinical Research’s operative presence in the region will empower local and foreign biotechnology companies to navigate the complexities of clinical trials with enhanced efficiency and broad expertise in the Netherlands.
Martin Krauss, Managing Director of FGK Clinical Research GmbH, says, “The decision to set up an operative team in the Netherlands is a natural progression of our sustained growth and our dedication to serving our clients where innovation thrives. The Dutch biotechnology landscape is incredibly promising, and we are eager to bring our extensive experience and full spectrum of clinical trial services directly to companies aiming for clinical studies in this region. Our local presence will facilitate closer collaboration, provide more tailored support, and ultimately accelerate the development of vital new therapies.”
FGK Clinical Research has a proven track record of successfully guiding biotechnology, pharmaceutical, and medical device companies through all phases of clinical development. With its new Dutch colleagues, FGK will offer its complete suite of internal services, including clinical trial management, monitoring and regulatory affairs with own local staff.
The expansion of our operative team into the Netherlands mirrors FGK’s successful organic expansion strategy which led to the establishment of several offices in Central Eastern Europe between 2006 and 2010 (Poland, Czech Republic, Hungary), the opening of a branch office in Berlin in 2020, the acquisition of Clinicology Ltd. in the UK in 2022 and the opening of a Boston office. This enhanced regional presence promotes even more efficient completion of clinical studies in this region.
“We understand the unique challenges and opportunities faced by biotechnology companies, particularly those focused on novel therapies,” adds Ursula Türcke, Senior Director Clinical Operations at FGK. “Our aim in the Netherlands is to become an indispensable partner, offering not just operational excellence but also strategic insights that help companies bring their innovations to patients faster and more effectively. We are excited to contribute to the continued growth and success of the Dutch biotech community.”
FGK Clinical Research remains committed to its core values of quality, efficiency, and customer orientation, ensuring that its new Dutch team upholds the same rigorous standards that have defined the company’s success for over two decades.
About FGK Clinical Research GmbH: FGK Clinical Research GmbH is a leading European full-service Contract Research Organization (CRO) providing comprehensive support for biotechnology, pharmaceutical, and medical device companies in their clinical development programs. Headquartered in Germany, FGK has a strong presence in Europe and the US, with over 240 highly qualified in-house employees dedicated to delivering efficient, and customer-oriented clinical research services.
Website: www.fgk-group.com/fgk-cro/
